



(11) **EP 2 694 959 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
25.12.2019 Bulletin 2019/52

(45) Date of publication and mention
of the grant of the patent:
13.11.2019 Bulletin 2019/46

(21) Application number: **12765178.4**

(22) Date of filing: **30.03.2012**

(51) Int Cl.:
C12Q 1/6886^(2018.01) A61K 31/517^(2006.01)
A61K 31/58^(2006.01)

(86) International application number:
PCT/US2012/031662

(87) International publication number:
WO 2012/135749 (04.10.2012 Gazette 2012/40)

(54) **BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS**

BIOMARKER ZUR VORHERSAGE DES ANSPRECHENS AUF KREBSBEHANDLUNGEN

MARQUEURS BIOLOGIQUES POUR PRÉVOIR LA SENSIBILITÉ À DES TRAITEMENTS DU
CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **01.04.2011 US 201161471036 P**

(43) Date of publication of application:
12.02.2014 Bulletin 2014/07

(60) Divisional application:
19203410.6

(73) Proprietor: **Genentech, Inc.**
South San Francisco, CA 94080-4990 (US)

(72) Inventors:
• **LIN, Kui**
South San Francisco
California 94080-4990 (US)
• **PUNNOOSE, Elizabeth**
South San Francisco
California 94080-4990 (US)

• **SESHAGIRI, Somasekar**
South San Francisco
California 94080-4990 (US)

(74) Representative: **Mewburn Ellis LLP**
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(56) References cited:
WO-A2-2008/049022 US-A1- 2006 142 178
US-A1- 2009 028 855 US-A1- 2011 038 862

• **Josep Tabernero ET AL: "Targeting the**
PI3K-Akt-mTOR pathway with GDC-0068, a novel
selective ATP competitive Akt inhibitor", , 9
March 2011 (2011-03-09), XP055153957,
Retrieved from the Internet:
URL: [http://www.arraybiopharma.com/files/20](http://www.arraybiopharma.com/files/2013/9810/8011/PubAttachment437.pdf)
13/9810/8011/PubAttachment437.pdf [retrieved
on 2014-11-19]

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- LIN K ET AL: "79 Preclinical characterization of GDC-0068, a novel selective ATP competitive inhibitor of Akt", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), page 33, XP027497767, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71784-5 [retrieved on 2010-11-01]
- MARGRITH E MATTMANN ET AL: "Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape/x-ms-", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 21, no. 9, 1 January 2011 (2011-01-01), pages 1309-1338, XP008159752, ISSN: 1354-3776, DOI: 10.1517/13543776.2011.587959
- A Cervantes ET AL: "Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors", , no. 619 9 November 2012 (2012-11-09), XP055153817, Retrieved from the Internet: URL: http://ac.els-cdn.com/S0959804912724164/1-s2.0-S0959804912724164-main.pdf?_tid=c f218536-6fc1-11e4-9243-00000aab0f6b&acdnat =1416384072_c6a32af2864559b484a7273ad71c8 a bc [retrieved on 2014-11-19]
- BARNETT ET AL.: 'Identification and characterization of pleckstrin-homology-domain independent and isoenzyme-specific Akt inhibitors' BIOCHEM. J. vol. 385, 2005, pages 399 - 408, XP055060694
- OKUZUMI ET AL.: 'Inhibitor Hijacking of Akt Activation' NAT. CHEM. BIOL. vol. 5, no. 7, July 2009, pages 484 - 493, XP055093045
- SKORSKI ET AL.: 'Transformation of hematopoietic cells by BCR/ABL requires activation of a PI- 3K/Akt-dependent pathway' EMBO J. vol. 16, no. 20, 1997, pages 6151 - 6161, XP055093052
- KIM ET AL.: 'Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias' BR. J. CANCER vol. 98, 2008, pages 1533 - 1535, XP055091514
- MAHADEVAN ET AL.: 'Discovery of a novel class of AKT pleckstrin homology domain inhibitors' MOL. CAN. THER. vol. 7, no. 9, September 2008, pages 2621 - 2632, XP055091519